---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-009199"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:13:26.696285+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tonix plans 70-90 sales reps for TNX-102 SL if FDA approves fibromyalgia NDA

## Summary
- Company plans to hire 70-90 sales representatives for TNX-102 SL conditional on FDA approval of NDA for fibromyalgia.
- TNX-102 SL NDA is under FDA review; approval decision would trigger commercial launch planning.
- Updated corporate presentation filed as Exhibit 99.01 for investor meetings; may contain nonpublic information.

## SEC filing metadata
- accession: 0001999371-25-009199
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125009199/0001999371-25-009199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125009199/tnxp-8k_071625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-009199
- JSON: https://secwatch.observer/filing/0001999371-25-009199.json
- Plain text: https://secwatch.observer/filing/0001999371-25-009199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.